Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.2.1.35: hyaluronoglucosaminidase

This is an abbreviated version!
For detailed information about hyaluronoglucosaminidase, go to the full flat file.

Word Map on EC 3.2.1.35

Reaction

hyaluronic acid hexasaccharide
+
H2O
=
hyaluronic acid disaccharide
 +
hyaluronic acid tetrasaccharide

Synonyms

BmHYA1, BPH-20, BTH, BVH, chondritinase I, chondroitin sulfate hydrolase, chondroitinase, chondroitinase I, Cumulase, Dietrich's hyaluronidase, EC 3.2.1.34, endo-alpha-N-acetyl-hexosaminidase, endo-beta-N-acetyl-D-hexosaminidases hydrolase, endo-beta-N-acetylhexosaminidase, HAase, HPH-20, HU, human PH-20, Hya, Hya-1, Hya1, Hyal, Hyal 1, HYAL 2, HYAL 3, HYAL 4, Hyal-1, Hyal-2, Hyal-3, Hyal-4, Hyal-Ba, HYAL1, HYAL1-v1, HYAL1-v3, Hyal2, HYAL3, HYAL3-v1, HYAL3-v2, HYAL4, HYAL5, hyaluronate 4-glycanohydrolase, hyaluronidase, hyaluronidase 1, hyaluronidase 2, hyaluronidase 3, hyaluronidase PH20, hyaluronidase-1, hyaluronidase-2, hyaluronidase-4, hyaluronidase-5, hyaluronoglucosaminidase, hyaluronoglucosaminidase 1, Hyaluronoglucosaminidase 1-type hyaluronidase, hyaluronoglucosaminidase 2, hyaluronoglucosidase, HYase, HYL, hylB, jaagsiekte sheep retrovirus receptor, LUCA-1, LUCA-2, Luca-3, LUCA2, MGEA5, Mu toxin, Neopermease, NNH1, NNH2, OTH, PH-20, rHuPH20, SFHYA1, SPAM1, sperm hyaluronidase 1, Sperm surface protein PH-20, spreading factor, testicular HAse, testicular hyaluronidase, vitrase, XKH1

ECTree

     3 Hydrolases
         3.2 Glycosylases
             3.2.1 Glycosidases, i.e. enzymes that hydrolyse O- and S-glycosyl compounds
                3.2.1.35 hyaluronoglucosaminidase

Inhibitors

Inhibitors on EC 3.2.1.35 - hyaluronoglucosaminidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2S)-2-(3,4-dimethoxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(2S)-2-[3,4-bis(benzyloxy)-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(5R)-3,4-bis(benzyloxy)-5-(1,2-dihydroxyethyl)furan-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(5R)-5-(1,2-dihydroxyethyl)-3,4-dimethoxyfuran-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(7S)-7-(1,2-dihydroxyethyl)-2,3-dihydrofuro[3,4-b][1,4]dioxin-5(7H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
2-aminobenzimidazole
0.04 mM, 92% inhibition
2-hydroxy-2-[(5R)-7-oxo-2,3,5,7-tetrahydrofuro[3,4-b][1,4]dioxin-5-yl]ethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
2-mercaptoethanol
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 2,2-dimethylpropaneperoxoate
-
inactive at concentrations less than 1.1 mM, at pH 5.0
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-(benzyloxy)hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-phenoxyhexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl benzenecarboperoxoate
-
33% inhibition at 1.43 mM
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [(1-prop-1-yn-1-ylpenta-1,2-dien-1-yl)oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl {[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy}ethaneperoxoate
-
-
3-(4-methylpiperazin-1-yl)-5-phenyl-1H-indole
-
0.05 mM, 23% inhibition in stains-all assay, pH 7.0
3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
-
6-chloromethyluracil
0.05 mM, 94% inhibition
6-palmitoyl-L-ascorbic acid
acetylated hyaluronic acid
-
-
-
Ag+
-
82% inhibition at 0.8 mM
ajmaline
-
-
apigenin
aristolochic acid
ascorbic acid palmitate
-
inhibition at pH 7: 99%, at pH 3.5: 99%
beta1,4-galacto-oligosaccharides
-
Br2+
0.2 M, about 40% loss of activity
-
butylated hydroxytoluene
-
-
chlorogenic acid
-
-
chondroitin O-sulfate
Chondroitin sulfates
-
-
cimicifugic acid H
-
-
cimicifugic acid I
-
-
cimicifugic acid J
-
-
clinopodic acid C
-
-
clinopodic acid E
-
-
curcumin
cysteine
-
complete inhibition from 0.012-1.2 mg/ml
D-isoascorbic acid
-
-
decyl gallate
-
-
dehydroascorbic acid
-
weak inhibition
dermatan O-sulfate
-
dermatan sulfate
dexamethasone
Dextran
-
-
Dextran sulfate
-
-
-
dimethyl sulfoxide
-
disodium cromoglycate
-
-
flavone
-
-
fukinolic acid
-
-
fully O-sulfonated chondroitin sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00135 mg/ml
-
fully O-sulfonated dermatan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00133 mg/ml
fully O-sulfonated heparan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00128 mg/ml
-
fully O-sulfonated heparin
-
50% inhibition at 0.00114 mg/ml
-
fully O-sulfonated hyaluronan
-
50% inhibition at 0.00078 mg/ml
glutathione
glycyrrhizic acid
-
-
heparan O-sulfate
-
IC50 = 0.00128 mg/ml
-
heparan sulfate
heparin
heparin O-sulfate
-
IC50 = 0.00114 mg/ml, competitive and non-competitive inhibitory effects
-
heptyl gallate
-
-
hexyl gallate
-
-
hyaluronan O-sulfate
-
IC50 = 0.00078 mg/ml
hyaluronic acid
-
inhibitory at high concentrations (0.73 g/l)
indomethacin
isorhamnetin
-
51.04% inhibition at 0.2 mM
kaempferol
L-Arginine-HCl
-
8% residual activity at 1 mM
L-ascorbic acid
L-ascorbic acid decanoate
-
-
L-ascorbic acid dodecanoate
-
-
L-ascorbic acid tridecanoate
-
-
L-ascorbic acid undecanoate
-
-
L-cysteine
Palamneus gravimanus
-
-
lansiumamide B
-
-
lepidepyrone
-
-
lycopic acid A
-
-
lycopic acid B
-
-
myricetin 3-O-beta-D-glucopyranoside
-
-
N-(4,6-dimethylpyridin-2-yl)-(1-ethylindole-3-yl)acetamide
-
inhibition at pH 7: 3%, but at pH 3.5: 134% activation
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 37%, but at pH 3.5: 117% activation
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 50%, but at pH 3.5: 120% activation
N-acetyl-L-cysteine
N-alpha-tosyl-L-lysine chloromethyl ketone
-
n-propyl gallate
-
-
nitrated hyaluronic acid
-
-
-
nonyl gallate
-
-
nordihydroguaiaretic acid
-
-
octyl 3,4-dihydroxybenzoate
-
-
octyl 3,5-dihydroxybenzoate
-
-
octyl gallate
-
-
partially sulfated neomycin
-
partially sulfated planteose
partially sulfated verbascose
-
polymer from gentisic acid
-
-
-
quercetin
quinol
-
irreversible inhibition
quinone
-
irreversible inhibition
reserpine
-
-
rosmarinic acid
-
-
rutin
schizotenuin A
-
-
serum protein
-
shomaside A
-
-
shomaside B
-
-
shomaside C
-
-
shomaside D
-
-
shomaside E
-
-
sorghum bran
-
the ability of ethanolic extracts of bran from six cultivated varieties of Sorghum bicolor to inhibit hyaluronidase activity in vitro is assessed. Each extract inhibits hyaluronidase activity with this order of potency: Sumac higher than Shanqui Red higher than Black higher than Mycogen higher than Fontanelle higher than White sorghum. Hyaluronidase inhibition correlate positively with total phenolic content and ferric reducing antioxidant power values for each bran extract. Inhibition is not only due to condensed tannins (proanthocyanidins) because the Black sorghum cultivar lacks condensed tannins but has abundant anthocyanins and other polyphenols
-
Sr2+
0.2 M, about 40% loss of activity
sulfated 2-hydroxyphenyl monolactobioside
-
IC50 is 0.025 mM
sulfated hydroquinone galactoside
Tannic acid
additional information
-